Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

HIV Infection, Immune-Based Interventions for

  • Guislaine Carcelain
  • Brigitte Autran
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_187-1


The overwhelming and continuous success of combination antiretroviral therapy (ART) is undermined by the inability to completely eradicate the HIV virus, requiring lifelong treatment, which is associated not only with side effects for the patients but also with substantial costs for the society. Immune-based interventions (IBTs) were developed during the last 15 years along two distinct paradigms. The first paradigm proposed during the late 1990s and early 2000s suggested either (1) using IBTs to help restore CD4 counts, in cases of failed immune reconstitution, or (2) using therapeutic vaccines to allow for prolonged treatment interruptions (TIs) and prevent disease progression by better controlling virus replication in the absence of treatment (Autran et al. 2004; Carcelain and Autran 2013; Pantaleo and Levy 2013). However, the SMART study, which demonstrated deleterious consequences of treatment interruptions, halted these TI-based strategies. The greater efficacy of new...


Immune Reconstitution Therapeutic Vaccine Plasma Viremia Immune Restoration Virus Relapse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P, Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112–6.Google Scholar
  2. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science. 2004;305(5681):205–8.CrossRefPubMedGoogle Scholar
  3. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011;6(3):181–7.CrossRefPubMedGoogle Scholar
  4. Autran B, Descours B, Bacchus C. Immune control of HIV-1 reservoirs. Curr Opin HIV AIDS. 2013;8(3):204–10.CrossRefPubMedGoogle Scholar
  5. Carcelain G, Autran B. Immune interventions in HIV infection. Immunol Rev. 2013;254(1):355–71.CrossRefPubMedGoogle Scholar
  6. Goh LE, McDade H, Kinloch S, Perrin L, Cooper D, Phillips A, et al. The QUEST trial, a paradigm of HIV collaborative research. Nat Med. 2000;6(11):1194.CrossRefPubMedGoogle Scholar
  7. Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol. 2011;32(3):131–7.CrossRefPubMedGoogle Scholar
  8. International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12(8):607–14.CrossRefGoogle Scholar
  9. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381(9883):2109–17.CrossRefPubMedGoogle Scholar
  10. Kinloch-de Loes S, Autran B. HIV-1 therapeutic vaccines. J Infect. 2002;44(3):152–9.CrossRefPubMedGoogle Scholar
  11. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol. 2006;24:657–79.CrossRefPubMedGoogle Scholar
  12. Massanella M, Negredo E, Clotet B, Blanco J. Immunodiscordant responses to HAART- mechanisms and consequences. Expert Rev Clin Immunol. 2013;9(11):1135–49.CrossRefPubMedGoogle Scholar
  13. McMichael AJ. HIV vaccines. Annu Rev Immunol. 2006;24:227–55.CrossRefPubMedGoogle Scholar
  14. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know. Nat Med. 2004;10(8):806–10.CrossRefPubMedGoogle Scholar
  15. Pantaleo G, Levy Y. Vaccine and immunotherapeutic interventions. Curr Opin HIV AIDS. 2013;8(3):236–42.CrossRefPubMedGoogle Scholar
  16. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323(5919):1304–7.CrossRefPubMedGoogle Scholar
  17. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.Google Scholar
  18. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010;329(5988):174–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Laboratory Immunity and InfectionUPMC University Paris VI, UMRS CR7ParisFrance
  2. 2.Laboratory Immunity and InfectionINSERM U1135ParisFrance